Kinnate Biopharma Accounts Payable

Kinnate Biopharma (KNTE) currently reports a accounts payable of $2M as of December 2023. That compares with $3M in the prior-year period — down 31.6% year over year. Use the charts on this page to explore Kinnate Biopharma's accounts payable history and peer comparisons.

Kinnate Biopharma's accounts payable decreased from $3M to $2M — a 31.6% year-over-year decrease (period ending December 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Kinnate Biopharma reported $2M in accounts payable as of December 2023. That compares with $3M in the prior-year period — down 31.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $2M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Kinnate Biopharma, and consider following KNTE for alerts when major investors trade the stock.

Kinnate Biopharma is classified in the Healthcare sector. On accounts payable, it currently shows $2M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing KNTE with unrelated industries.